Literature DB >> 15659311

Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta.

Saoirse E O'Sullivan1, David A Kendall, Michael D Randall.   

Abstract

The vascular effects of cannabinoids have been compared in the rat isolated aorta. Delta9-Tetrahydrocannabinol (THC), anandamide and N-arachidonoyl-dopamine (NADA) all caused vasorelaxation to similar degrees in pre-constricted aortae. Vasorelaxation to THC was inhibited by in vivo pre-treatment with pertussis toxin (10 microg/kg) or with the synthetic cannabinoid CP55,940 (((-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol), acutely or chronically), exposure to capsaicin in vitro (10 microM for 1 h), and de-endothelialisation. Vasorelaxation to anandamide was only inhibited by pertussis toxin and chronic CP55,940 pre-treatment (0.4 mg/kg for 11 days). Vasorelaxation to NADA was inhibited by pertussis toxin and chronic CP55,940 pre-treatment, and by de-endothelialisation. The vasorelaxant effects of the cannabinoids were not inhibited by cannabinoid CB1 receptor antagonism; however, vasorelaxation to both CP55,940 and THC was inhibited by cannabinoid CB2 receptor antagonism. Vasorelaxation to all cannabinoids was enhanced in the presence of indomethacin (10 microM). THC also caused vasoconstriction of the aorta while anandamide, NADA, CP55,940 and WIN 55,212-2 (R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4benzoxazin-yl]-(1-naphthalenyl)methanone mesylate) did not. The vasoconstrictor effects of THC were inhibited by in vivo pre-treatment with pertussis toxin or CP55,940, acute exposure to CP55,940, cannabinoid CB1 receptor antagonism and cyclooxygenase inhibition. These results demonstrate the opposing vascular effects of cannabinoids in the rat aorta, and although vasorelaxation to each of the cannabinoids is of similar magnitude, it is mediated through different pathways. This gives further indication of the different vascular actions of cannabinoid compounds.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15659311     DOI: 10.1016/j.ejphar.2004.11.056

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

Review 1.  N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets.

Authors:  Mark Connor; Chris W Vaughan; Robert J Vandenberg
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  GPR55 and the vascular receptors for cannabinoids.

Authors:  C R Hiley; S S Kaup
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

Review 3.  Biosynthesis, degradation and pharmacological importance of the fatty acid amides.

Authors:  Emma K Farrell; David J Merkler
Journal:  Drug Discov Today       Date:  2008-04-03       Impact factor: 7.851

4.  Vasorelaxation to N-oleoylethanolamine in rat isolated arteries: mechanisms of action and modulation via cyclooxygenase activity.

Authors:  A J Wheal; S P H Alexander; M D Randall
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 5.  Endothelial atypical cannabinoid receptor: do we have enough evidence?

Authors:  Alexander I Bondarenko
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

6.  Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects.

Authors:  Wen Jiang; Yun Zhang; Lan Xiao; Jamie Van Cleemput; Shao-Ping Ji; Guang Bai; Xia Zhang
Journal:  J Clin Invest       Date:  2005-10-13       Impact factor: 14.808

7.  The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine.

Authors:  Sherry Shu-Jung Hu; Heather B Bradshaw; Valery M Benton; Jay Shih-Chieh Chen; Susan M Huang; Alberto Minassi; Tiziana Bisogno; Kim Masuda; Bo Tan; Robert Roskoski; Benjamin F Cravatt; Vincenzo Di Marzo; J Michael Walker
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2009-06-30       Impact factor: 4.006

8.  Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.

Authors:  E Herradón; M I Martín; V López-Miranda
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

9.  Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats.

Authors:  W-S Vanessa Ho; Sheila M Gardiner
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

Review 10.  Is the cardiovascular system a therapeutic target for cannabidiol?

Authors:  Christopher P Stanley; William H Hind; Saoirse E O'Sullivan
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.